⏱️ 7 min read | A team of researchers developed a simple platform to test how toxic different types of HTT protein clumps are using a laboratory worm model. They showed that certain types of clumps are harmful to the worms, while others are not.
HDBuzz
January 2026: This Month in Huntington’s Disease Research
⏱️ 9 min read | January 2026 HD research recap: SKY-0515 shows promising safety data, community advocacy helps secure critical FDA meeting for AMT-130, plus new insights on sleep, vaccines, and symptom management. Read the full roundup!
Phase 1 results announced for Skyhawk’s drug SKY-0515
Skyhawk Therapeutics shared results for SKY-0515, a drug designed to lower huntingtin. The drug appeared generally safe, with 60% reduction of huntingtin in blood at the highest dose tested. This data is an encouraging step as larger trials continue.
Huntington’s Disease Community Advocacy Helps Land Critical FDA Meeting for AMT-130
⏱️5 min read |The Huntington’s disease community’s unprecedented mobilization helped secure a high-priority FDA meeting to discuss the path forward for AMT-130.
Better Sleep, Better Function: New Study Links Sleep Quality to Clinical Outcomes in Huntington’s Disease
⏱️6 min read | Most people with HD report sleep problems, & new research suggests sleep quality is linked to many aspects of living with the disease. Wearables tracked people with HD for a year & revealed better sleep & strength training might help.